Comparative prognostic performance of FIB-4, AIP, and TyG for all-cause and cardiovascular mortality in FLI-defined MASLD: a nationally representative NHANES 2011–2018 cohort study

Abstract Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is driven by both fibrosis and cardiometabolic dysfunction, but the relative prognostic value of fibrosis- and metabolism-related indices for near-term mortality remains uncertain. Aim To compare the associations and discriminatory performance of the fibrosis-4 index (FIB-4), atherogenic index of plasma (AIP), and triglyceride-glucose (TyG) index for all-cause mortality (ACM) and cardiovascular mortality (CVDM) in adults with FLI-defined MASLD. Methods This prospective cohort analysis included 4,037 adults with FLI-defined MASLD from NHANES 2011–2018. Mortality was ascertained through linkage to the National Death Index through December 31, 2019. Survey-weighted Cox models, restricted cubic splines, and 5-year time-dependent ROC analyses were used to evaluate associations and discrimination. Age-stratified analyses were performed because age is a component of FIB-4. Results During a median follow-up of approximately 4.5 years, 222 all-cause deaths and 66 cardiovascular deaths occurred. In fully adjusted age-stratified models, each 1-SD increase in FIB-4 was associated with higher ACM risk in participants aged < 65 years (HR 1.24, 95% CI 1.09–1.41) and ≥ 65 years (HR 1.34, 95% CI 1.20–1.50). FIB-4 was also associated with CVDM among participants aged ≥ 65 years (HR 1.37, 95% CI 1.19–1.59), whereas AIP and TyG were not significantly associated with CVDM in this age stratum. As standalone markers, FIB-4 showed higher 5-year discrimination than AIP and TyG for ACM (AUC 0.763 vs. 0.494 and 0.522) and CVDM (AUC 0.785 vs. 0.505 and 0.557). In sensitivity analyses using US-FLI-defined MASLD, the association of FIB-4 with ACM remained significant, and additional adjustment for lipid- and glucose-lowering medications did not materially alter the primary estimates. Conclusions In adults with FLI-defined MASLD, FIB-4 showed stronger near-term mortality risk stratification than AIP and TyG as standalone markers. The cardiovascular findings should be interpreted cautiously given the limited number of events and their sensitivity to the operational MASLD definition.

Authors

Institutions

Publication Details

Journal
Egyptian Liver Journal
Published
2026-11-14
DOI
https://doi.org/10.1186/s43066-026-00566-9
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparative prognostic performance of FIB-4, AIP, and TyG for all-cause and cardiovascular mortality in FLI-defined MASLD: a nationally representative NHANES 2011–2018 cohort study

Y Liu, Ning Kang, Zhichao Zheng
8 links
Egyptian Liver Journal
Liver Disease Diagnosis and Treatment
article

Comparative prognostic performance of FIB-4, AIP, and TyG for all-cause and cardiovascular mortality in FLI-defined MASLD: a nationally representative NHANES 2011–2018 cohort study

Y Liu, Ning Kang, Zhichao Zheng
article en

Abstract

Abstract Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is driven by both fibrosis and cardiometabolic dysfunction, but the relative prognostic value of fibrosis- and metabolism-related indices for near-term mortality remains uncertain. Aim To compare the associations and discriminatory performance of the fibrosis-4 index (FIB-4), atherogenic index of plasma (AIP), and triglyceride-glucose (TyG) index for all-cause mortality (ACM) and cardiovascular mortality (CVDM) in adults with FLI-defined MASLD. Methods This prospective cohort analysis included 4,037 adults with FLI-defined MASLD from NHANES 2011–2018. Mortality was ascertained through linkage to the National Death Index through December 31, 2019. Survey-weighted Cox models, restricted cubic splines, and 5-year time-dependent ROC analyses were used to evaluate associations and discrimination. Age-stratified analyses were performed because age is a component of FIB-4. Results During a median follow-up of approximately 4.5 years, 222 all-cause deaths and 66 cardiovascular deaths occurred. In fully adjusted age-stratified models, each 1-SD increase in FIB-4 was associated with higher ACM risk in participants aged < 65 years (HR 1.24, 95% CI 1.09–1.41) and ≥ 65 years (HR 1.34, 95% CI 1.20–1.50). FIB-4 was also associated with CVDM among participants aged ≥ 65 years (HR 1.37, 95% CI 1.19–1.59), whereas AIP and TyG were not significantly associated with CVDM in this age stratum. As standalone markers, FIB-4 showed higher 5-year discrimination than AIP and TyG for ACM (AUC 0.763 vs. 0.494 and 0.522) and CVDM (AUC 0.785 vs. 0.505 and 0.557). In sensitivity analyses using US-FLI-defined MASLD, the association of FIB-4 with ACM remained significant, and additional adjustment for lipid- and glucose-lowering medications did not materially alter the primary estimates. Conclusions In adults with FLI-defined MASLD, FIB-4 showed stronger near-term mortality risk stratification than AIP and TyG as standalone markers. The cardiovascular findings should be interpreted cautiously given the limited number of events and their sensitivity to the operational MASLD definition.

Egyptian Liver JournalVol. 16(1)
Guangdong Academy of Medical Sciences (CN), Guangdong Provincial People's Hospital (CN)
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon